The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis

Kim, Na Young; Ryoo, UiNam; Lee, Dong−Yun; Kim, Min Jae; Yoon, Byung-Koo; Choi, DooSeok

doi:10.1016/j.ejogrb.2010.08.008

Cited by 24 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A maximum of 6 months of treatment with GnRH analogues such as Triptorelin is currently licensed for ovarian downregulation [15,16]. This is due to the potential for reduction in bone mineral density (BMD) that follows prolonged periods of hypo-oestrogenisation [13,17].…”

Section: Introductionmentioning

confidence: 99%

A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Alshehre

Duffy

Jones

et al. 2020

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background: Chronic cyclic pelvic pain (CCPP) affects women's quality of life and pituitary downregulation is often used for symptomatic relief. However, prolonged suppression of ovarian function is associated with menopausal side effects and can lead to osteoporosis. Currently, the use of gonadotropin releasing hormone agonists (GnRHa) for treatment of CCPP is usually restricted to 6-9 months, limiting their efficacy. There is limited information regarding safety and efficacy with longer-term use. The aim of this study is to examine the safety and efficacy of long-term (24 months) pituitary down-regulation with the GnRHa (Triptorelin SR) with add-back therapy (ABT) using Tibolone for symptom relief in women with CCPP. Methods: A single-arm, prospective clinical trial at a Tertiary University Teaching Hospital of 27 patients receiving Triptorelin SR (11.25 mg) and Tibolone (2.5 mg). Outcomes measures were the safety of treatment assessed by clinical examination, haematological markers, liver and renal function tests and bone mineral density (BMD) at 12, 18 and 24 months as well as at 6 months post-treatment. Pain and health-related quality of life (HR-QoL) assessed using the endometriosis health profile (EHP-30) and chronic pain grade (CPG) questionnaires. Results: There was no evidence for any significant harmful effects on any of the measured haematological, renal or liver function tests. Although results regarding the effect on BMD are not conclusive there is an increased risk of development of osteopaenia after 12 months of treatment. Pain and HRQoL assessments showed significant improvement during medication, but with deterioration after treatment cessation.

show abstract

Section: Introductionmentioning

confidence: 99%

A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Alshehre

Duffy

Jones

et al. 2020

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…Kim et al considered that addition of Tibolone or estradiol valerate from the second cycle of GnRHa after operation until the end of treatment can reduce uterine bleeding and symptoms of estrogen deficiency. They found that the curative effect on endometriosis was the same, but that the side‐effect of GnRHa was significantly reduced when compared with GnRHa alone …”

Section: Discussionmentioning

confidence: 99%

Curative effect of 1.88‐mg and 3.75‐mg gonadotrophin‐releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study

Tang

et al. 2017

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Laparoscopy is recognized as the first option for diagnosis and treatment of endometriosis, but the rate of pain recurrence after conservative surgery is high. GnRH agonists have long been used successfully in the treatment of endometriosis [1,11–15], but because of their adverse effects (loss of bone minerals and vasomotor symptoms), physicians need better choices.…”

Section: Discussionmentioning

confidence: 99%

Effects of simvastatin in prevention of pain recurrences after surgery for endometriosis

et al. 2013

View full text Add to dashboard Cite

BackgroundTo compare efficacy of simvastatin with GnRHa (Decapeptyl 3.75 mg) on endometriosis-related pains following surgery for endometriosis.Material/MethodsSixty women with pelvic endometriosis, after laparoscopic diagnosis and conservative laparoscopic surgery, were treated with either simvastatin (n=30) for 16 weeks or Decapeptyl (n=30) every 4 weeks for 4 doses.ResultsUsing VAS, the score of dyspareunia, dysmenorrhea, and pelvic pain 6 months after laparoscopic surgery declined significantly in both groups (p=0.001), but the difference between results of the 2 groups was not significant (p>0.05).ConclusionsBoth treatment modalities showed comparable effectiveness in the treatment of pains related to endometriosis.

show abstract

The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis

Cited by 24 publications

References 23 publications

A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Curative effect of 1.88‐mg and 3.75‐mg gonadotrophin‐releasing hormone agonist on stage III–IV endometriosis: Randomized controlled study

Effects of simvastatin in prevention of pain recurrences after surgery for endometriosis

Contact Info

Product

Resources

About